New cancer drug HY0001a enters human trials for advanced solid tumors

NCT ID NCT07069062

Recruiting now Disease control Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called HY0001a in 261 people with advanced solid tumors who have no other treatment options. The study aims to find a safe dose and see if the drug can shrink tumors. It is currently recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HY0001a
What this could lead to: If this works, it could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early phase 1/2 trial with only 261 participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Peking University Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100143, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.